This study identifies the conserved bridging domain on HCV E1E2 as a target for neutralizing antibodies from diverse lineages, showing additivity with neutralizing face antibodies.

Cell Reports · Aug 1, 2026Peer-reviewedImmunology

Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2

Yen Thi Kim Nguyen, Fang Chen, Erick Giang, Swati Saha, Lynn A. Ueno, Christopher Chen, Corey T. Watson, Netanel Tzarum, Ian A. Wilson, Mansun Law, Robyn L. Stanfield

This study identifies two classes of HCV E2 neutralizing antibodies from non-human primates immunized with a recombinant E1E2, showing similarity to human antibodies.

npj Vaccines · Apr 21, 2026Peer-reviewedImmunology

Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design

Linling He, Yi-Zong Lee, Yi-Nan Zhang, Maddy L. Newby, Benjamin M. Janus, Fabrizio G. Gonzalez, Garrett Ward, Connor DesRoberts, Shr-Hau Hung, Erick Giang, Joel D. Allen, Liudmila Kulakova, Eric A. Toth, Thomas R. Fuerst, Mansun Law, , Jiang Zhu

The paper designs, characterizes, and tests a soluble HCV E1E2 heterodimer and self-assembling nanoparticles for vaccine development.

Nature Communications · Feb 11, 2026Peer-reviewedMicrobiology

B cell transcriptomics reveals lasting dysregulation and rapid decline of protective memory after hepatitis C cure

Fang Chen, Erick Giang, Padmaja Natarajan, Tony S. Mondala, Steven Robert Head, Sing Chau Lau, Aishwarya Sundaresan, Liudmila Kulakova, Xiaohe Lin, Jasneet Aneja, Raiees Andrabi, Yun Zhang, Richard H. Scheuermann, Eric A. Toth, Thomas R. Fuerst, , Mansun Law

This study shows that B cells in hepatitis C patients retain dysregulated transcriptional profiles after cure, with sustained TNF signaling driving chronic inflammation and loss of protective memory.

bioRxiv · Oct 24, 2025 · PreprintImmunology